VolitionRX Shares Are Trading Higher After the Company Announced a Study Showed Its Nu.Q Lung Cancer Test Achieved 92% Sensitivity and 89% Positive Predictive Value in Differentiating Malignant From Benign Pulmonary Nodules.
VolitionRX Shares Are Trading Higher After the Company Announced a Study Showed Its Nu.Q Lung Cancer Test Achieved 92% Sensitivity and 89% Positive Predictive Value in Differentiating Malignant From Benign Pulmonary Nodules.
VolitionRX的股票在公司宣佈一項研究後交易上漲，該研究顯示其Nu.Q肺癌檢測在區分惡性和良性肺結節方面達到了92%的靈敏度和89%的陽性預測值。
VolitionRX Shares Are Trading Higher After the Company Announced a Study Showed Its Nu.Q Lung Cancer Test Achieved 92% Sensitivity and 89% Positive Predictive Value in Differentiating Malignant From Benign Pulmonary Nodules.
VolitionRX的股票在公司宣佈一項研究後交易上漲，該研究顯示其Nu.Q肺癌檢測在區分惡性和良性肺結節方面達到了92%的靈敏度和89%的陽性預測值。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間